Sourcing Exosomes in Delaware
Licensed Delaware practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Delaware buyers need their own professional license and NPI; the Pharmacy-Wholesale permit is the supplier’s obligation, not the purchaser’s.
Delaware is one of the few states whose legislature has voted on regenerative medicine and enacted nothing: the Delaware Regenerative Medicine Act of 2007 was a research ethics bill, and it failed in the House. What a Delaware practice actually plans around is simpler than in most states: one licensing agency, full practice authority for experienced APRNs, and no sales tax paperwork.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Delaware? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Delaware
ExaVeyra ships to licensed practices in all 50 states, Delaware included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Delaware professional license in good standing, verifiable through DELPROS, the Division of Professional Regulation’s online license portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- No resale exemption certificate: Delaware levies no sales tax, and sellers pay a gross receipts tax instead. A practice purchasing for resale registers for a Delaware business license and gross receipts tax with the Division of Revenue.
How the state permits wholesale distribution
Delaware licenses pharmaceutical establishments through the Board of Pharmacy, within the Division of Professional Regulation, and the Pharmacy-Wholesale permit is unusually broad in subject: it covers facilities that distribute drugs, toilet preparations, dentifrices, and cosmetics on a wholesale basis to persons other than the ultimate consumer, and facilities that provide or coordinate warehousing or logistics for dangerous drugs or devices in intrastate or interstate commerce. An out-of-state distributor shipping into Delaware applies through the same process as an in-state facility and submits license verification from its home state. The permit sits with the distributor, not with the purchasing practice.
24 Del. C. §§ 2540, 2540A, 2542 · Delaware Board of Pharmacy, Division of Professional Regulation
Delaware regenerative-medicine law
Delaware has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No Delaware statute addresses unapproved regenerative therapy, so federal law is the only layer. The legislature has voted on the subject exactly once: SB 5, the Delaware Regenerative Medicine Act of the 144th General Assembly, which addressed embryonic stem cell research ethics and human cloning rather than clinical practice, passed the Senate and was defeated in the House in June 2007. Practice in this area is governed by the Medical Practice Act, the nursing statute, and the boards that administer them, alongside federal law.
How this applies to exosomes
Delaware has enacted no stem cell authorization law like Florida, Texas, or Georgia, no disclosure law like California, and no documentation statute like Tennessee. Its one legislative attempt, the Delaware Regenerative Medicine Act of 2007, was a research ethics bill that failed in the House, and it would not have reached clinical practice even if enacted. There is therefore no Delaware definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles in any case, outside the stem cell category entirely. Exosome products in Delaware are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Delaware practice
Because experienced advanced practice registered nurses hold full practice authority in Delaware, there are two workable structures rather than one. An APRN-led practice can evaluate and order within APRN scope once the transition requirements are satisfied. A physician-led practice delegates conventionally, and a medical director is still needed where a procedure falls outside APRN scope or where a payer requires one. Every profession involved is licensed through the Division of Professional Regulation, so verification runs through the single DELPROS portal.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Delaware Board of Medical Licensure and Discipline may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. The same Board licenses physician assistants. |
| NP / APRN | Delaware defines full practice authority in its nursing statute: 24 Del. C. 1902 describes the advanced practice registered nurse as an independent licensed practitioner with authority for advanced assessment, diagnosing, prescribing, and ordering. The Board of Nursing administers a collaborative transition period before an APRN practices independently, so a newly licensed APRN works under a collaborative agreement first. |
| PA | Physician assistants are licensed by the Board of Medical Licensure and Discipline and practice within the scope their collaborating physician establishes under the Medical Practice Act. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Delaware expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Where an advanced practice registered nurse holds full practice authority, that provider can be the APRN. Confirm current expectations with the Board of Medical Licensure and Discipline and the Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Delaware does not codify a corporate practice of medicine prohibition the way Texas, New York, or New Jersey do, and no primary source states a bright-line ownership rule. Professional entities and management services arrangements are the usual structures, and because the position rests on general licensing law rather than an explicit statute, ownership structure here is a question for Delaware counsel and the Division of Professional Regulation rather than one a guide should answer with a percentage.
Cold chain into Delaware
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Delaware order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Wilmington | New Castle | Largest Delaware market, served alongside the Philadelphia metro corridor. |
| Newark | New Castle | University-anchored market with a growing aesthetic segment. |
| Dover | Kent | Capital market serving central Delaware practices. |
| Middletown | New Castle | Fast-growing southern New Castle County suburb. |
| Rehoboth Beach | Sussex | Coastal resort market with seasonal aesthetic demand. |
| Lewes | Sussex | Cape Region market with concierge and dermatology practices. |
- Delaware orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every shipment arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot.
Practice types we supply in Delaware
Delaware licensing and verification
Delaware Board of Medical Licensure and Discipline
Licenses physicians and physician assistants; one of the DPR boards behind the DELPROS portal.
Delaware Board of Nursing
Licenses RNs, LPNs, and APRNs, and administers the APRN transition to independent practice.
Delaware Board of Pharmacy
Issues the Pharmacy-Wholesale permit that distributors shipping into Delaware hold.
Delaware Division of Revenue
Business licensing and gross receipts tax; Delaware levies no sales tax.
Delaware sourcing questions
- Does Delaware have a stem cell law?
- No. Delaware has no stem cell authorization law, disclosure law, or documentation statute. Its one legislative attempt, the Delaware Regenerative Medicine Act of 2007, was a research ethics bill addressing embryonic stem cell research and human cloning; it passed the Senate and was defeated in the House in June 2007, and nothing has been enacted since. Exosome products in Delaware are governed by federal law.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification saying so. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- Can a nurse practitioner run a practice in Delaware without a physician?
- Delaware defines full practice authority in its nursing statute and describes the APRN as an independent licensed practitioner. The Board of Nursing administers a collaborative transition period first, so a newly licensed APRN works under a collaborative agreement before practicing independently. A medical director is still needed where a procedure falls outside APRN scope or where a payer requires one.
- Does my Delaware clinic need a wholesale permit to buy exosomes?
- No. The Pharmacy-Wholesale permit under 24 Del. C. 2540 is held by the distributor shipping into Delaware, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Does a Delaware practice need a resale certificate?
- Delaware levies no sales tax, so there is no resale exemption certificate of the kind most states use. Sellers pay a gross receipts tax instead, and a practice purchasing for resale registers for a Delaware business license and gross receipts tax with the Division of Revenue.
- How long does cold-chain shipping take to Delaware?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Delaware Board of Pharmacy, Distributor licensure (accessed 16 October 2026)
- Delaware Code, title 24, chapter 25, pharmaceutical establishments (24 Del. C. 2540 et seq.) (accessed 16 October 2026)
- Delaware Code, title 24, chapter 19 (Nursing) (accessed 16 October 2026)
- Delaware SB 5, Delaware Regenerative Medicine Act (144th General Assembly), bill detail (accessed 16 October 2026)
- Delaware Board of Medical Licensure and Discipline (accessed 16 October 2026)
- Delaware Division of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page says accompanies every Delaware order.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: ISEV criteria for identifying MSC-derived small extracellular vesicles, the source-material category behind the perinatal MSC-EV products this page describes, and the identity attributes a complete characterization package reports.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: ISEV position on manufacturing and safety documentation for EV-based products in trials, supporting this page’s framing that clinical use of exosomes runs through regulated research rather than any state permission.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.